about
Epigenetics and airways diseaseHistone deacetylase 6 plays a role as a distinct regulator of diverse cellular processesHistone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach.Histone modification enzymes: novel targets for cancer drugs.Decreased histone deacetylase 4 is associated with human osteoarthritis cartilage degeneration by releasing histone deacetylase 4 inhibition of runt-related transcription factor-2 and increasing osteoarthritis-related genes: a novel mechanism of humHistone deacetylase inhibition and the regulation of cell growth with particular reference to liver pathobiology.Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance?Histone deacetylation: an important mechanism in inflammatory lung diseases.HDAC6 and ovarian cancer.A class of their own: exploring the nondeacetylase roles of class IIa HDACs in cardiovascular diseaseHistone deacetylase inhibitors and cell death.Histone deacetylase inhibitors in hematological malignancies and solid tumors.Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance.BET Protein BRDT Complexes With HDAC1, PRMT5, and TRIM28 and Functions in Transcriptional Repression During Spermatogenesis.Azetidinones as zinc-binding groups to design selective HDAC8 inhibitors.Combinatorial In Silico Strategy towards Identifying Potential Hotspots during Inhibition of Structurally Identical HDAC1 and HDAC2 Enzymes for Effective Chemotherapy against Neurological Disorders.Critical role of the HDAC6-cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect.Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of Class II HDAC isoforms.
P2860
Q25256981-19585869-AB35-4294-A8FE-31385BA957E4Q26830233-8AB1386A-A9FD-4AE8-8C05-A4F8BB60C893Q30251920-832B069F-8C7F-478C-A8FD-492CCBB9EE14Q33789848-966B21F5-85AA-4652-B665-B39357E3D0E8Q34322087-94E61911-2F79-4726-B7D8-8DB6B04F8C5AQ34695447-16E5E9F7-E78E-472F-B841-AA5E57878194Q35893218-9CA615F6-0ADF-4F57-84C7-6A33EDB2838AQ36179533-93970C70-3498-46EF-8D30-AFCD2F7E1CB5Q36674117-1830AD48-7893-4898-AFB4-1B2F8930B584Q36913610-660020F5-DCF7-44FF-BE47-518459D7F1FCQ37218059-ADADE5F2-6828-47E3-B941-FC9CF8C24D79Q38217666-EF2B7094-9AEA-4898-95EC-A8B272EFA70CQ38344675-84333EF0-F99F-43EF-817C-392CBD8CEEF5Q40321046-5A7B4397-62D0-4999-AE1B-0B4E85B913B7Q41203569-9FF1B23D-33D0-4172-9F70-8D379A30C592Q42575755-E000417E-03ED-491C-A4C6-7CFB4C2B59B7Q43263389-2C7DCCA0-3DFC-4815-844E-64B4F19CA511Q45953663-B8B26FE1-8C47-48DD-B31E-C9E47DE0D10EQ47363826-F0D73039-3326-4541-BD62-17497441B625Q50693776-82E571D9-37BB-403C-98A3-F91424CC099C
P2860
description
im Juni 2001 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в червні 2001
@uk
name
The emerging role of class II histone deacetylases
@en
The emerging role of class II histone deacetylases
@nl
type
label
The emerging role of class II histone deacetylases
@en
The emerging role of class II histone deacetylases
@nl
prefLabel
The emerging role of class II histone deacetylases
@en
The emerging role of class II histone deacetylases
@nl
P2093
P2860
P356
P1476
The emerging role of class II histone deacetylases
@en
P2093
Eric Verdin
Franck Dequiedt
Wolfgang Fischle
P2860
P304
P356
10.1139/O01-116
P577
2001-06-01T00:00:00Z